Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session

LBA5 - A phase 2 study of neoadjuvant SHR-1701 with or without chemotherapy (chemo) followed by surgery or radiotherapy (RT) in stage III unresectable NSCLC (uNSCLC)


07 Dec 2022


Proffered Paper session


Tumour Site

Non-Small Cell Lung Cancer


Yi-Long Wu


Annals of Oncology (2022) 16 (suppl_1): 100104-100104. 10.1016/iotech/iotech100104


Y. Wu1, Q. Zhou2, Y. Pan3, X. Yang3, Y. Zhao4, G. Han5, Q. Pang6, Z. Zhang6, Q. Wang7, J. Yao8, H. Wang9, W. Yang9, B. Liu10, Q. Chen11, X. Du11, K. Cai12, B. Li13, J. Shuang14, L. Song14, W. Shi15

Author affiliations

  • 1 Guangdong Province People's Hospital, Guangzhou/CN
  • 2 Affiliated Hospital of Guangdong Medical University, Zhanjiang/CN
  • 3 Guangdong Provincial People's Hospital, Guangzhou/CN
  • 4 Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou/CN
  • 5 HuBei Cancer Hospital, Wuhan/CN
  • 6 Tianjin Medical University Cancer Institute & Hospital, Tianjin/CN
  • 7 Sichuan Cancer Hospital, Chengdu/CN
  • 8 The First Affiliated Hospital of Henan University of Science and Technology, Luoyang/CN
  • 9 Hunan Cancer Hospital, Changsha/CN
  • 10 Cancer Hospital Affiliated to Harbin Medical University,, Heilongjiang/CN
  • 11 Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou/CN
  • 12 Nanfang Hospital of Southern Medical University, Guangzhou/CN
  • 13 Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan/CN
  • 14 Jiangsu Hengrui Pharmaceutical Co., Ltd., Shanghai/CN
  • 15 Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai/CN


Login to access the resources on OncologyPRO.

Abstract LBA5


Consolidation immunotherapy (IO) after chemoradiation is the standard of care for stage III uNSCLC. Addition of IO-based induction therapy may further improve outcome, partly by enabling surgery. SHR-1701 is a novel anti-PD-L1/TGFβRII fusion protein. We assessed neoadjuvant SHR-1701 ± chemo, followed by surgery or RT in untreated stage III uNSCLC without EGFR/ALK alterations.


Pts were given 3 cycles of neoadjuvant SHR-1701 (30 mg/kg Q3W) ± chemo (paclitaxel 175 mg/m2 Q3W + carboplatin AUC=5 Q3W). Pts with PD-L1 TPS <50% received combo-therapy (arm A) and those with PD-L1 TPS ≥50% were randomized (1:1) to receive combo-therapy (arm B) or SHR-1701 alone (arm C). After assessment by MDT, pts received surgery or definitive RT (60 Gy/30 fractions) + concurrent cisplatin (30 mg/m2 QW), followed by SHR-1701 for 16 cycles. The primary endpoints were post-induction ORR and event-free survival (EFS).


107 pts were enrolled (arm A/B/C, n=88/9/10; median age, 59 y; squamous NSCLC, 76.6%; stage IIIA/B/C, 25.2%/43.9%/29.9%). In all pts, the post-induction and best overall ORR were 56.1% (95% CI 46.2-65.7) and 70.1% (60.5-78.6). mEFS was 18.2 mo (95% CI 11.8-not reached [NR]). Efficacy by study arm is shown in Table 1. 27 (25.2% of 107; baseline stage IIIA/B/C, 37.0%/44.4%/18.5%) pts underwent surgery (lobectomy/bilobectomy/pneumonectomy, 88.9%/7.4%/3.7%); all achieved R0 resection. Among them, 12 (44.4%) MPR and 7 (25.9%) pCR were recorded. Nodal downstaging was seen in 14 pts (51.9%; pN2 to pN0/1, 8/14 [57.1%]; pN3 to pN0-2, 6/9 [66.7%]). mEFS was NR in resected pts. Grade ≥3 TRAEs occurred in 77 (72.0%) pts; all with frequency ≥10% were hematotoxicities. No new safety signals were identified. Table: LBA5

Efficacy by study arm

Arm A (n=88) Arm B (n=9) Arm C (n=10) Arm A+B (n=97) All pts (n=107)
ORR (95% CI),% 55.7 (44.7-66.3) 77.8 (40.0-97.2) 40.0 (12.2-73.8) 57.7 (47.3-67.7) 56.1 (46.2-65.7)
DCR (95% CI)*,% 93.2 (85.7-97.5) 88.9 (51.8-99.7) 90.0 (55.5-99.7) 92.8 (85.7-97.0) 92.5 (85.8-96.7)
Best overall
ORR (95% CI),% 70.5 (59.8-79.7) 77.8 (40.0-97.2) 60.0 (26.2-87.8) 71.1 (61.0-79.9) 70.1 (60.5-78.6)
mEFS (95% CI), mo 18.2 (11.5-NR) 11.8 (3.3-NR) NR (2.0-NR) 14.9 (11.5-NR) 18.2 (11.8-NR)
Surgery conversion, n (%) 21 (23.9) 3 (33.3) 3 (30.0) 24 (24.7) 27 (25.2)
*Same results for best overall DCR. †Starting from the first study dose. Data cutoff was Jul. 31, 2022.


SHR-1701 ± chemo showed promising antitumor activity with a tolerable safety profile in stage III uNSCLC. Some pts could switch from unresectable to resectable and get much better efficacy. Phase 3 investigation is warranted.

Clinical trial identification


Legal entity responsible for the study

Jiangsu Hengrui Pharmaceuticals, Co., Ltd.


Jiangsu Hengrui Pharmaceuticals, Co., Ltd.


Y. Wu: Financial Interests, Personal, Other, Honoraria: AstraZeneca, Lilly, Roche, Pfizer, Boehringer Ingelheim, MSD Oncology, Bristol Myers Squibb, Hengrui; Financial Interests, Personal, Advisory Role: AstraZeneca, Roche, Boehringer Ingelheim, Takeda; Financial Interests, Personal, Research Grant: Boehringer Ingelheim, Roche, Pfizer, Bristol Myers Squibb. J. Shuang, L. Song, W. Shi: Financial Interests, Personal, Full or part-time Employment: Hengrui. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.